Latest Pharma Insights
Shah Capital Blasts Novavax Strategy In New Letter To Board
The hedge fund said it plans to vote against the vaccine maker’s board nominees and criticized what it called insufficient cost-cutting by the company.
Scrip - April 8, 2026
The hedge fund said it plans to vote against the vaccine maker’s board nominees and criticized what it called insufficient cost-cutting by the company.
Scrip - April 8, 2026
FDA And Industry Reach ‘Agreement In Principle’ On MDUFA VI Framework
The US FDA and medtech industry are closing in on wrapping up the latest round of MDUFA negotiations as they have agreed to begin drafting the commitment letter required by Congress. No further MDUFA meetings are scheduled.
Medtech Insight - April 8, 2026
The US FDA and medtech industry are closing in on wrapping up the latest round of MDUFA negotiations as they have agreed to begin drafting the commitment letter required by Congress. No further MDUFA meetings are scheduled.
Medtech Insight - April 8, 2026
Dexcom’s CEO Jake Leach Discusses New Trial Data, Focus ‘To Enhance User Experience,’ Stelo Upgrade
New Dexcom data shows CGM monitoring improves HbA1c, supports insulin optimization, and reduces DKA risk. In an interview with Medtech Insight, CEO Jake Leach outlines plans to expand access to CGM, obtain Medicare coverage, and offers a preview of the enhanced Stelo app.
Medtech Insight - April 8, 2026
New Dexcom data shows CGM monitoring improves HbA1c, supports insulin optimization, and reduces DKA risk. In an interview with Medtech Insight, CEO Jake Leach outlines plans to expand access to CGM, obtain Medicare coverage, and offers a preview of the enhanced Stelo app.
Medtech Insight - April 8, 2026
No New Hardware Required: BD’s HemoSphere Stream To Bring Continuous BP Monitoring To Any Bedside
Most hospital patients having complex surgery are monitored with intermittent blood pressure readings every 3 to 5 minutes. BD's HemoSphere Stream Module is designed to change that by turning the bedside monitors already installed in hospitals into continuous monitoring platforms.
Medtech Insight - April 8, 2026
Most hospital patients having complex surgery are monitored with intermittent blood pressure readings every 3 to 5 minutes. BD's HemoSphere Stream Module is designed to change that by turning the bedside monitors already installed in hospitals into continuous monitoring platforms.
Medtech Insight - April 8, 2026
Finance Watch: Three VC Mega-Rounds Already In April For Syneron, Sidewinder, Stipple
Private Company Edition: Syneron completed a $150m series B round, Sidewinder raised $137m in series B cash and Stipple Bio came out of stealth mode with $100m in series A funding. Also, BSM Biotech Holding launched in Germany to create IND-ready start-ups.
Scrip - April 8, 2026
Private Company Edition: Syneron completed a $150m series B round, Sidewinder raised $137m in series B cash and Stipple Bio came out of stealth mode with $100m in series A funding. Also, BSM Biotech Holding launched in Germany to create IND-ready start-ups.
Scrip - April 8, 2026
Prestige Launches Hayfever Eye Drops in the UK
Prestige Consumer Healthcare has expanded its UK TheraTears range with the launch of a new sodium cromoglicate–based hay fever relief eye drop, targeting rising demand ahead of the 2026 pollen season.
HBW Insight - April 8, 2026
Prestige Consumer Healthcare has expanded its UK TheraTears range with the launch of a new sodium cromoglicate–based hay fever relief eye drop, targeting rising demand ahead of the 2026 pollen season.
HBW Insight - April 8, 2026
Route 92 Medical Raises $50m To Grow Stroke Intervention Business
Funding follows strong clinical results for “super-bore” HiPoint catheter in ischemic stroke and will be used to expand global commercial efforts
Medtech Insight - April 8, 2026
Funding follows strong clinical results for “super-bore” HiPoint catheter in ischemic stroke and will be used to expand global commercial efforts
Medtech Insight - April 8, 2026
EU Notified Bodies Say MDR/IVDR Proposals Would Carry Increased Risk To Public Health
Performance-based oversight that rewards regulatory compliance and manufacturer performance would be safer and more effective than the European Commission’s plan for reduced surveillance across the board, says TEAM-NB.
Medtech Insight - April 8, 2026
Performance-based oversight that rewards regulatory compliance and manufacturer performance would be safer and more effective than the European Commission’s plan for reduced surveillance across the board, says TEAM-NB.
Medtech Insight - April 8, 2026
Brinsupri’s Resounding HS Failure Won’t Hold Insmed Back
Low expectations of success in hidradenitis suppurativa and growth in its established indication mean Brinsupri’s Phase II trial miss is unlikely to concern investors too much.
Scrip - April 8, 2026
Low expectations of success in hidradenitis suppurativa and growth in its established indication mean Brinsupri’s Phase II trial miss is unlikely to concern investors too much.
Scrip - April 8, 2026
Lotus To Take Over Sandoz’s Portfolio In The Philippines
Lotus Pharmaceutical continues to expand its presence in its native region of Southeast Asia, where the firm marked substantial growth of 91% over the past year.
Generics Bulletin - April 8, 2026
Lotus Pharmaceutical continues to expand its presence in its native region of Southeast Asia, where the firm marked substantial growth of 91% over the past year.
Generics Bulletin - April 8, 2026
Aeon Finances Creak As Biosimilar Momentum Builds
Aeon has reported positive FDA feedback and analytical progress for its ABP-450 biosimilar to Botox, but faces renewed NYSE non-compliance after deepening losses.
Generics Bulletin - April 8, 2026
Aeon has reported positive FDA feedback and analytical progress for its ABP-450 biosimilar to Botox, but faces renewed NYSE non-compliance after deepening losses.
Generics Bulletin - April 8, 2026
Apotex Moves Into Denosumab As Canadian Competition Accelerates
Apotex has secured Health Canada approval for its denosumab biosimilar Denoza, joining a growing field of Prolia- and Xgeva-referenced rivals as competition intensifies in Canada’s osteoporosis and oncology biologics market.
Generics Bulletin - April 8, 2026
Apotex has secured Health Canada approval for its denosumab biosimilar Denoza, joining a growing field of Prolia- and Xgeva-referenced rivals as competition intensifies in Canada’s osteoporosis and oncology biologics market.
Generics Bulletin - April 8, 2026
US Opens Farxiga To Generics After Pricing Overhaul
FDA approvals for generic dapagliflozin mark the first potential US entries following Farxiga’s patent expiry, intensifying competition in a multi-billion-dollar market already reshaped by Medicare price negotiation and AstraZeneca’s authorized generic strategy.
Generics Bulletin - April 8, 2026
FDA approvals for generic dapagliflozin mark the first potential US entries following Farxiga’s patent expiry, intensifying competition in a multi-billion-dollar market already reshaped by Medicare price negotiation and AstraZeneca’s authorized generic strategy.
Generics Bulletin - April 8, 2026
India’s High-Stakes Oral Semaglutide Battle And Novo’s ‘SNAC’ Test
The battle royale for semaglutide dominance in India continues with court action expected to play out later this month pertaining to the oral version of Novo’s GLP-1 receptor agonist which appears to have the carrier molecule SNAC as the key infringement trigger against Torrent and Dr Reddy's.
Scrip - April 8, 2026
The battle royale for semaglutide dominance in India continues with court action expected to play out later this month pertaining to the oral version of Novo’s GLP-1 receptor agonist which appears to have the carrier molecule SNAC as the key infringement trigger against Torrent and Dr Reddy's.
Scrip - April 8, 2026
Licensing Deal For Progeria Drug Could Benefit Zydus In More Ways Than One
Zydus Lifesciences’ previously announced licensing of Korean firm PRG’s Progerinin might not just add to its drug portfolio but also might be a positive given the recently announced US pharma tariffs and exemptions
Scrip - April 8, 2026
Zydus Lifesciences’ previously announced licensing of Korean firm PRG’s Progerinin might not just add to its drug portfolio but also might be a positive given the recently announced US pharma tariffs and exemptions
Scrip - April 8, 2026
GLP-1s Were Just The Start: The Next Wave Of Obesity Therapies
Obesity is no longer just a growth market – it’s a battleground. In Vivo examines where the space stands today and how the next wave of therapies could change everything.
In Vivo - April 8, 2026
Obesity is no longer just a growth market – it’s a battleground. In Vivo examines where the space stands today and how the next wave of therapies could change everything.
In Vivo - April 8, 2026
Shah Capital Blasts Novavax Strategy In New Letter To Board
The hedge fund said it plans to vote against the vaccine maker’s board nominees and criticized what it called insufficient cost-cutting by the company.
Scrip - April 8, 2026
The hedge fund said it plans to vote against the vaccine maker’s board nominees and criticized what it called insufficient cost-cutting by the company.
Scrip - April 8, 2026
Finance Watch: Three VC Mega-Rounds Already In April For Syneron, Sidewinder, Stipple
Private Company Edition: Syneron completed a $150m series B round, Sidewinder raised $137m in series B cash and Stipple Bio came out of stealth mode with $100m in series A funding. Also, BSM Biotech Holding launched in Germany to create IND-ready start-ups.
Scrip - April 8, 2026
Private Company Edition: Syneron completed a $150m series B round, Sidewinder raised $137m in series B cash and Stipple Bio came out of stealth mode with $100m in series A funding. Also, BSM Biotech Holding launched in Germany to create IND-ready start-ups.
Scrip - April 8, 2026
Brinsupri’s Resounding HS Failure Won’t Hold Insmed Back
Low expectations of success in hidradenitis suppurativa and growth in its established indication mean Brinsupri’s Phase II trial miss is unlikely to concern investors too much.
Scrip - April 8, 2026
Low expectations of success in hidradenitis suppurativa and growth in its established indication mean Brinsupri’s Phase II trial miss is unlikely to concern investors too much.
Scrip - April 8, 2026
India’s High-Stakes Oral Semaglutide Battle And Novo’s ‘SNAC’ Test
The battle royale for semaglutide dominance in India continues with court action expected to play out later this month pertaining to the oral version of Novo’s GLP-1 receptor agonist which appears to have the carrier molecule SNAC as the key infringement trigger against Torrent and Dr Reddy's.
Scrip - April 8, 2026
The battle royale for semaglutide dominance in India continues with court action expected to play out later this month pertaining to the oral version of Novo’s GLP-1 receptor agonist which appears to have the carrier molecule SNAC as the key infringement trigger against Torrent and Dr Reddy's.
Scrip - April 8, 2026
Licensing Deal For Progeria Drug Could Benefit Zydus In More Ways Than One
Zydus Lifesciences’ previously announced licensing of Korean firm PRG’s Progerinin might not just add to its drug portfolio but also might be a positive given the recently announced US pharma tariffs and exemptions
Scrip - April 8, 2026
Zydus Lifesciences’ previously announced licensing of Korean firm PRG’s Progerinin might not just add to its drug portfolio but also might be a positive given the recently announced US pharma tariffs and exemptions
Scrip - April 8, 2026
FDA And Industry Reach ‘Agreement In Principle’ On MDUFA VI Framework
The US FDA and medtech industry are closing in on wrapping up the latest round of MDUFA negotiations as they have agreed to begin drafting the commitment letter required by Congress. No further MDUFA meetings are scheduled.
Medtech Insight - April 8, 2026
The US FDA and medtech industry are closing in on wrapping up the latest round of MDUFA negotiations as they have agreed to begin drafting the commitment letter required by Congress. No further MDUFA meetings are scheduled.
Medtech Insight - April 8, 2026
Dexcom’s CEO Jake Leach Discusses New Trial Data, Focus ‘To Enhance User Experience,’ Stelo Upgrade
New Dexcom data shows CGM monitoring improves HbA1c, supports insulin optimization, and reduces DKA risk. In an interview with Medtech Insight, CEO Jake Leach outlines plans to expand access to CGM, obtain Medicare coverage, and offers a preview of the enhanced Stelo app.
Medtech Insight - April 8, 2026
New Dexcom data shows CGM monitoring improves HbA1c, supports insulin optimization, and reduces DKA risk. In an interview with Medtech Insight, CEO Jake Leach outlines plans to expand access to CGM, obtain Medicare coverage, and offers a preview of the enhanced Stelo app.
Medtech Insight - April 8, 2026
No New Hardware Required: BD’s HemoSphere Stream To Bring Continuous BP Monitoring To Any Bedside
Most hospital patients having complex surgery are monitored with intermittent blood pressure readings every 3 to 5 minutes. BD's HemoSphere Stream Module is designed to change that by turning the bedside monitors already installed in hospitals into continuous monitoring platforms.
Medtech Insight - April 8, 2026
Most hospital patients having complex surgery are monitored with intermittent blood pressure readings every 3 to 5 minutes. BD's HemoSphere Stream Module is designed to change that by turning the bedside monitors already installed in hospitals into continuous monitoring platforms.
Medtech Insight - April 8, 2026
Route 92 Medical Raises $50m To Grow Stroke Intervention Business
Funding follows strong clinical results for “super-bore” HiPoint catheter in ischemic stroke and will be used to expand global commercial efforts
Medtech Insight - April 8, 2026
Funding follows strong clinical results for “super-bore” HiPoint catheter in ischemic stroke and will be used to expand global commercial efforts
Medtech Insight - April 8, 2026
EU Notified Bodies Say MDR/IVDR Proposals Would Carry Increased Risk To Public Health
Performance-based oversight that rewards regulatory compliance and manufacturer performance would be safer and more effective than the European Commission’s plan for reduced surveillance across the board, says TEAM-NB.
Medtech Insight - April 8, 2026
Performance-based oversight that rewards regulatory compliance and manufacturer performance would be safer and more effective than the European Commission’s plan for reduced surveillance across the board, says TEAM-NB.
Medtech Insight - April 8, 2026
Prestige Launches Hayfever Eye Drops in the UK
Prestige Consumer Healthcare has expanded its UK TheraTears range with the launch of a new sodium cromoglicate–based hay fever relief eye drop, targeting rising demand ahead of the 2026 pollen season.
HBW Insight - April 8, 2026
Prestige Consumer Healthcare has expanded its UK TheraTears range with the launch of a new sodium cromoglicate–based hay fever relief eye drop, targeting rising demand ahead of the 2026 pollen season.
HBW Insight - April 8, 2026
Lotus To Take Over Sandoz’s Portfolio In The Philippines
Lotus Pharmaceutical continues to expand its presence in its native region of Southeast Asia, where the firm marked substantial growth of 91% over the past year.
Generics Bulletin - April 8, 2026
Lotus Pharmaceutical continues to expand its presence in its native region of Southeast Asia, where the firm marked substantial growth of 91% over the past year.
Generics Bulletin - April 8, 2026
Aeon Finances Creak As Biosimilar Momentum Builds
Aeon has reported positive FDA feedback and analytical progress for its ABP-450 biosimilar to Botox, but faces renewed NYSE non-compliance after deepening losses.
Generics Bulletin - April 8, 2026
Aeon has reported positive FDA feedback and analytical progress for its ABP-450 biosimilar to Botox, but faces renewed NYSE non-compliance after deepening losses.
Generics Bulletin - April 8, 2026
Apotex Moves Into Denosumab As Canadian Competition Accelerates
Apotex has secured Health Canada approval for its denosumab biosimilar Denoza, joining a growing field of Prolia- and Xgeva-referenced rivals as competition intensifies in Canada’s osteoporosis and oncology biologics market.
Generics Bulletin - April 8, 2026
Apotex has secured Health Canada approval for its denosumab biosimilar Denoza, joining a growing field of Prolia- and Xgeva-referenced rivals as competition intensifies in Canada’s osteoporosis and oncology biologics market.
Generics Bulletin - April 8, 2026
US Opens Farxiga To Generics After Pricing Overhaul
FDA approvals for generic dapagliflozin mark the first potential US entries following Farxiga’s patent expiry, intensifying competition in a multi-billion-dollar market already reshaped by Medicare price negotiation and AstraZeneca’s authorized generic strategy.
Generics Bulletin - April 8, 2026
FDA approvals for generic dapagliflozin mark the first potential US entries following Farxiga’s patent expiry, intensifying competition in a multi-billion-dollar market already reshaped by Medicare price negotiation and AstraZeneca’s authorized generic strategy.
Generics Bulletin - April 8, 2026
GLP-1s Were Just The Start: The Next Wave Of Obesity Therapies
Obesity is no longer just a growth market – it’s a battleground. In Vivo examines where the space stands today and how the next wave of therapies could change everything.
In Vivo - April 8, 2026
Obesity is no longer just a growth market – it’s a battleground. In Vivo examines where the space stands today and how the next wave of therapies could change everything.
In Vivo - April 8, 2026